Pharmacokinetics, Immunogenicity, and Safety of a Modified YTE Antibody in Healthy Adults.
A new antibody shows promise with a long half-life and detectable presence in nasal fluid for potential respiratory protection.
This randomized controlled trial examined Pharmacokinetics, Immunogenicity, and Safety of a Modified YTE Antibody in Healthy Adults. The PubMed abstract reports PK analysis of a single dose of REGN17092 administered IV or SC suggests that REGN17092 has a half-life of 80-90 days and showed detectable penetration into nasal fluid.
What the study was
- Study design
- Randomized controlled trial
- Population
- Human participants or patients described in the abstract
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clinical pharmacology in drug development
Why it surfaced
Randomized controlled trial with human evidence; score reflects novelty, clinical relevance, design quality, and population or unmet-need value under the v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.